Related references
Note: Only part of the references are listed.Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces Off' time in Parkinson's disease:: A double-blind, randomized, multicenter clinical trial (6002-US-005)
Peter A. LeWitt et al.
ANNALS OF NEUROLOGY (2008)
Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctuations
Robert A. Hauser et al.
MOVEMENT DISORDERS (2008)
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
M. Stacy et al.
NEUROLOGY (2008)
Oscillations in the basal ganglia under normal conditions and in movement disorders
Plamen Gatev et al.
MOVEMENT DISORDERS (2006)
Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease
P Jenner
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
Parkinson's disease home diary: Further validation and implications for clinical trials
RA Hauser et al.
MOVEMENT DISORDERS (2004)
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias
F Calon et al.
BRAIN (2004)
Comparing dopamine agonists in Parkinson's disease
U Bonuccelli
CURRENT OPINION IN NEUROLOGY (2003)
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease
P Jenner
CURRENT OPINION IN NEUROLOGY (2003)
Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD
RA Hauser et al.
NEUROLOGY (2003)
Molecular mechanisms of selective dopaminergic neuronal death in Parkinson's disease
A Barzilai et al.
TRENDS IN MOLECULAR MEDICINE (2003)
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia
M Lundblad et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Limitations of current Parkinson's disease therapy
O Rascol et al.
ANNALS OF NEUROLOGY (2003)
Neuroinflammatory processes in Parkinson's disease
S Hunot et al.
ANNALS OF NEUROLOGY (2003)
An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines
CW Olanow et al.
NEUROLOGY (2001)
Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys
T Kanda et al.
EXPERIMENTAL NEUROLOGY (2000)
Share Paper
